Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ120212050,17
KB101610170,59
PKN74,2474,280,84
Msft0,58
Nokia4,7344,739-0,82
IBM0,75
Mercedes-Benz Group AG51,3851,40,08
PFE0,99
09.06.2025 9:19:54
Indexy online
AD Index online
select
AD Index online
 

  • 06.06.2025
Iridex Corp (NASDAQ Cons)
Závěr k 6.6.2025 Změna (%) Změna (USD) Objem obchodů (ks)
0,9732 1,38 0,01 48 872
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiIRIDEX Corp
TickerIRIX
Kmenové akcie:Ordinary Shares
RICIRIX.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky28.12.2024
Poslední známé čtvrtletní výsledky29.03.2025
Počet zaměstnanců k 28.12.2024 93
Akcie v oběhu k 08.05.2025 16 789 027
MěnaUSD
Kontaktní informace
Ulice1212 Terra Bella Ave
MěstoMOUNTAIN VIEW
PSČ94043-1824
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 509 404 700
Fax16509404710

Business Summary: IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Financial Summary: BRIEF: For the three months ended 29 March 2025, IRIDEX Corp revenues increased 1% to $11.9M. Net loss decreased 51% to $1.7M. Revenues reflect G6 segment increase of 8% to $3.2M, Other segment increase of 2% to $2.1M, Asia/Pacific Rim segment increase of 37% to $3.4M, Rest of the Americas segment increase of 32% to $392K. Lower net loss reflects Selling/General/Admin. Expense decrease of 34% to $2.4M (expense).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICS2007Electromedical Apparatus Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
SICElectromedical Equipment
SICElectromedical Equipment
SICSurgical And Medical Instruments



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardScott Shuda5901.01.202401.01.2024
President, Chief Executive Officer, Chief Operating Officer, DirectorPatrick Mercer5222.11.2024
Chief Financial OfficerRomeo Dizon6719.03.2025